iBio, Inc. (NYSE:IBIO) has a beta value of -6.19 and has seen 2,670,046 shares traded in the recent trading session. The company, currently valued at $285.13 Million, closed the recent trade at $1.28 per share which meant it lost -$0.07 on the day or -5.19% during that session. The IBIO stock price is -482.03% off its 52-week high price of $7.45 and 25% above the 52-week low of $0.96. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.05 Million shares traded. The 3-month trading volume is 8.32 Million shares.
The consensus among analysts is that iBio, Inc. (IBIO) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 1 have rated it as a Hold, with 1 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is $0.
iBio, Inc. (NYSE:IBIO) trade information
Despite being -5.19% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Wednesday, Apr 28 when the IBIO stock price touched $1.45 or saw a rise of 12.07%. Year-to-date, iBio, Inc. shares have moved 21.43%, while the 5-day performance has seen it change -4.14%. Over the past 30 days, the shares of iBio, Inc. (NYSE:IBIO) have changed -21.78%. Short interest in the company has seen 16.39 Million shares shorted with days to cover at 1.97.
Wall Street analysts have a consensus price target for the stock at $3, which means that the shares’ value could jump 134.38% from the levels at last check today. The projected low price target is $3 while the price target rests at a high of $3. In that case, then, we find that the latest price level in today’s session is +134.38% off the targeted high while a plunge would see the stock lose 134.38% from the levels at last check today.
iBio, Inc. (IBIO) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +8% over the past 5 years. Earnings growth for 2021 is a modest +35.4%.
iBio, Inc. (NYSE:IBIO)’s Major holders
Insiders own 0.99% of the company shares, while shares held by institutions stand at 14.17% with a share float percentage of 14.31%. Investors are also buoyed by the number of investors in a company, with iBio, Inc. having a total of 115 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 11.58 Million shares worth more than $12.15 Million. As of December 30, 2020, Blackrock Inc. held 5.36% of shares outstanding.
The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 3.7 Million shares as of December 30, 2020. The firm’s total holdings are worth over $3.88 Million and represent 1.71% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are iShares Russell 2000 ETF and Vanguard Extended Market Index Fund. As of March 30, 2021, the former fund manager holds about 2.35% shares in the company for having 5076734 shares of worth $7.82 Million while later fund manager owns 2.85 Million shares of worth $3Million as of December 30, 2020, which makes it owner of about 1.32% of company’s outstanding stock.